8 June 2021 in Clinical and Translational Oncology
Methylation of N6-adenosine (m6A) is the most prevalent internal RNA modification and is especially common among the messenger RNAs. These m6A modifications regulate splicing, translocation, stability and translation of RNA through dynamic and reversible interactions with m6A-binding proteins, namely the writers, erasers and readers. RNA methyltransferases catalyze the m6A modifications, while demethylases reverse this methylation. Deregulation of the m6A modification process has been implicated in human carcinogenesis, including melanoma—which carries one of the highest mutant rates. In this review, we provide an up-to-date summary of m6A regulation and its biological impacts on normal and cancer cells, with emphasis on the deregulation of m6A modification and m6A regulators in melanoma. In addition, we highlight the prospective potential of exploiting m6A modification in the treatment of melanoma and non-cancer diseases.
7 November 2022 in Oncology Reports
Lung cancer is the most common type of cancer and the leading cause of cancer‑associated death worldwide. Despite the availability of various treatments such as surgery, chemoradiotherapy, targeted drugs and immunotherapy, treatment is expensive and the prognosis remains poor. At present, lung cancer drugs and treatment programs remain in a state of continuous exploration and research to improve the prognosis, and to reduce the pain and economic burden for the patients. Type 2 diabetes is a common chronic disease in middle‑aged and elderly patients, leading to significantly increased complications of cardiovascular and cerebrovascular diseases. Epidemiology shows that type 2 diabetes also increases the incidence of malignant tumors, including lung, liver, colorectal and pancreatic cancer. Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes. Metformin has a hypoglycemic effect and a biological antitumor impact, reducing the incidence of various tumors, including lung cancer, and improving the prognosis of patients with tumors. The anti‑lung cancer effect of metformin involves a variety of mechanisms that can improve the therapeutic effect and prognosis of lung cancer, as a single drug or in combination with other therapies. The present study aims to review the associated literature and the therapeutic effects of metformin on lung cancer.
29 November 2019 in Oncology Letters
Aberrant DNA methylations have been reported to be significantly associated with lung squamous cell cancer (LUSC). The aim of this study was to investigate the DNA methylation‑driven genes in LUSC by integrative bioinformatics analysis. In the present study, methylation‑driven genes in LUSC were screened out, and survival analysis related to these genes was performed to confirm their value in prognostic assessment. Gene expression and methylation data were downloaded from The Cancer Genome Atlas (TCGA), and the MethylMix algorithm was used to identify methylation‑driven genes. ConsensusPathDB was used to perform Gene Ontology and pathway enrichment analysis of methylation‑driven genes. Survival analysis was performed to investigate the correlation with prognosis. In total, 52 differentially expressed methylation‑driven genes were identified in LUSC and adjacent tissues. Survival analysis showed that DQX1, GPR75, STX12, and TRIM61 could serve as independent prognostic biomarkers. In addition, the combined methylation and gene expression survival analysis revealed that the combined expression level of the genes ALG1L, DQX1, and ZNF418 alone can be used as a prognostic marker or drug target. Methylation of four sites of gene ZNF418, four sites of ZNF701, two sites of DQX1, and four sites of DCAF4L2 was significantly associated with survival. The present study provides an important bioinformatic and relevant theoretical basis for subsequent early diagnosis and prognostic assessment of LUSC.
18 August 2022 in Disease Markers
Background. Lung adenocarcinoma is the most common lung cancer subtype and accounts for the highest proportion of cancer-related deaths. The tumor microenvironment influences prognostic outcomes in lung adenocarcinoma (LUAD). Materials and Methods. We used the ESTIMATE algorithm (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) to investigate the role of microenvironment-related genes and stromal cells in lung adenocarcinoma prognosis. This analysis was done on lung adenocarcinoma cases from The Cancer Genome Atlas (TCGA). The cases were divided into high and low groups on the basis of immune and stromal scores, respectively. Results. There were close correlations between immune scores with prognosis and disease stage. There were 367 differentially expressed genes. Combining the Gene Expression Omnibus (GEO) database, we found 14 prognosis-related genes. Results. Based on the enrichment levels of the immune cell types, we clustered LUAD into Immunity_H and Immunity_L subtypes. Most of these genes were upregulated in Immunity_H subtype. Finally, using the Human Protein Atlas (HPA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases, most of the proteins corresponding to prognostic genes were verified to be differentially expressed between the tumor and normal groups. Conclusions. The key genes identified in this study are involved in molecular mechanisms of LUAD.
1 August 2025 in Translational Cancer Research
Background: Epithelial-mesenchymal transition (EMT) plays an important role in the pathogenesis of lung adenocarcinoma (LUAD). In this study, we aimed to construct a prognostic signature based on EMT that could predict the prognosis of patients with LUAD. Methods: The messenger RNA (mRNA) expression profiles and the clinical data were downloaded from The Cancer Genome Atlas (TCGA) as the training set while data from the Gene Expression Omnibus (GEO) served as the validation set. Differentially expressed EMT-related genes (EMTGs) were identified from the training dataset. Univariate and multivariate Cox regression analyses were employed to develop a gene signature from the EMTGs to predict overall survival (OS) time. The prediction performance of the signature was tested using the time-dependent receiver operating characteristic (ROC) curve. The signature was verified in the TCGA dataset and the external dataset, GSE30219. A corresponding nomogram was also constructed to predict the prognosis of patients with LUAD. The expression of the prognostic genes at the protein level was investigated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. Gene set enrichment analysis was conducted to reveal the biological pathways associated with the high-risk group and the low-risk group. Results: A set of 79 differentially expressed EMTGs were identified. An EMT-related signature was constructed which classified patients with LUAD into two subgroups based on the median risk score. In the ROC curve analysis, the prognostic signature had a moderate discrimination accuracy for the 1-, 3-, and 5-year survival rate with areas under the curve (AUCs) of 0.732, 0.675, 0.702 in TCGA training set, respectively and 0.813, 0.672, 0.706 in the GSE30219 validation set, respectively. The established nomogram effectively predicted the OS of patients with LUAD. Conclusions: The novel EMT-related signature established in this study is a robust and independent prognostic indicator for patients with LUAD. This signature is expected to improve the personalized management of patients with LUAD.